Genmab A (GMAB) Operating Expenses (2018 - 2026)
Genmab A's (GMAB) quarterly Operating Expenses came in at -$716.0 million in Q1 2026, down 35.86% YoY from -$1.1 billion in Q1 2025, and up 56.74% on a QoQ basis from -$1.7 billion in Q3 2025.
Genmab A (GMAB) Operating Expenses (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 8 years of Operating Expenses data on file, last reported at -$716.0 million in Q1 2026.
- Quarterly Operating Expenses fell 35.86% year-over-year to -$716.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 billion (down 11.96% YoY) and the FY2025 annual result came in at $2.7 billion, up 23.55% from the prior year.
- Operating Expenses advanced to -$716.0 million in Q1 2026, from -$1.7 billion in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.0 billion in Q4 2023 to a low of -$1.7 billion in Q3 2025.
- A 4-year average of -$627.8 million and a median of -$873.0 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2025 — Operating Expenses slipped 6.02% — and 2026, when it plunged 35.86%.
- Tracing GMAB's Operating Expenses over 4 years: stood at $2.0 billion in 2023, then tumbled by 176.0% to -$1.5 billion in 2024, then fell by 7.75% to -$1.7 billion in 2025, then surged by 56.74% to -$716.0 million in 2026.
- The last three Operating Expenses figures came in at -$716.0 million (Q1 2026), -$1.7 billion (Q3 2025), and -$1.1 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 780.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 780.00 Mn |
| Mar 31, 2026 | -716.00 Mn |
| Sep 30, 2025 | -1.66 Bn |
| Jun 30, 2025 | -1.09 Bn |
| Mar 31, 2025 | -527.00 Mn |
| Sep 30, 2024 | -1.54 Bn |
| Jun 30, 2024 | -1.03 Bn |
| Mar 31, 2024 | -487.00 Mn |
| Dec 31, 2023 | 2.02 Bn |
| Mar 31, 2021 | -76.00 Mn |
| Sep 30, 2020 | -866.00 |
| Mar 31, 2020 | -2.00 Mn |
| Dec 31, 2019 | -689.00 |
| Sep 30, 2019 | -689.11 Mn |
| Dec 31, 2018 | -398.42 Mn |